Search Results
Search for other papers by Antonella Giampietro in
Google Scholar
PubMed
Search for other papers by Sabrina Chiloiro in
Google Scholar
PubMed
Search for other papers by Claudio Urbani in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Martin Ove Carlsson in
Google Scholar
PubMed
Search for other papers by Francesca Dassie in
Google Scholar
PubMed
Search for other papers by Nunzia Prencipe in
Google Scholar
PubMed
Search for other papers by Marta Ragonese in
Google Scholar
PubMed
Search for other papers by Roy Gomez in
Google Scholar
PubMed
Search for other papers by Simona Granato in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavò in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Pietro Maffei in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
Introduction Acromegaly is a chronic, slowly progressive disease characterized by somatic disfigurement, particularly of the extremities, and systemic manifestations ( 1 ). In most cases, acromegaly occurs as a consequence of a growth hormone
Search for other papers by Nelma Veronica Marques in
Google Scholar
PubMed
Search for other papers by Luiz Eduardo Armondi Wildemberg in
Google Scholar
PubMed
Search for other papers by Monica R Gadelha in
Google Scholar
PubMed
Introduction Pasireotide long-acting release is a multireceptor-targeted somatostatin receptor ligand (SRL) approved to treat adult patients with acromegaly ( 1 ). In patients, this second-generation SRL has been shown to be effective in
School of Medicine, Western Sydney University, Sydney, Australia
Search for other papers by Prishila Fookeerah in
Google Scholar
PubMed
Westmead Clinical School, University of Sydney, Sydney, Australia
Search for other papers by Winny Varikatt in
Google Scholar
PubMed
Westmead Clinical School, University of Sydney, Sydney, Australia
Search for other papers by Meena Shingde in
Google Scholar
PubMed
Department of Neurosurgery, Westmead Hospital, Sydney, Australia
Search for other papers by Mark A J Dexter in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Sydney, Australia
Search for other papers by Mark McLean in
Google Scholar
PubMed
–132 years). Of the nine tumours, eight presented with acromegaly clinically. One tumour presented with visual field defects and only expressed gonadotrophins on immunostaining although without biochemical or clinical evidence of excess gonadotrophin
Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands
Department of Neurosurgery, University Neurosurgical Centre Holland (UNCH), Leiden University Medical Centre, Haaglanden Medical Centre and Haga Teaching Hospitals, Leiden and The Hague, The Netherlands
Search for other papers by Amir H Zamanipoor Najafabadi in
Google Scholar
PubMed
Search for other papers by Merel van der Meulen in
Google Scholar
PubMed
Search for other papers by Ana Luisa Priego Zurita in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Wouter R van Furth in
Google Scholar
PubMed
Search for other papers by Evangelia Charmandari in
Google Scholar
PubMed
Search for other papers by Olaf Hiort in
Google Scholar
PubMed
Search for other papers by Alberto M Pereira in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Diana Vitali in
Google Scholar
PubMed
Search for other papers by Johan P de Graaf in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
. Pituitary adenomas comprise non-hormone-producing adenomas and adenomas producing an excess of growth hormone (acromegaly), adrenocorticotropic hormone (Cushing’s disease), prolactin (prolactinoma), thyrotropin hormone (TSH-producing adenoma), and
Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands
Search for other papers by Savi R Shishkov in
Google Scholar
PubMed
Università “Federico II” di Napoli, Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Naples, Italy
Search for other papers by Luigi Tuccillo in
Google Scholar
PubMed
Search for other papers by Violeta M Iotova in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Iris CM Pelsma in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology & Metabolism, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Alberto M Pereira in
Google Scholar
PubMed
Adult Chair of MTG Pituitary of Endo-ERN
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by the Endo-ERN Reference Centers of the Main Thematic Group: Hypothalamic and Pituitary Conditions, Endo-ERN Pituitary Transition of Care Study Group in
Google Scholar
PubMed
1 , indicated that hypopituitarism was managed by all RCs and physicians, while acromegaly was managed by the fewest RCs ( N = 15/30, 50%) and physicians ( n = 18/46, 39%). In 13 (43%) of the responding RCs and by 10 (22%) of the responding
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jesper Krogh in
Google Scholar
PubMed
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Peter Plomgaard in
Google Scholar
PubMed
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Ruth Frikke-Schmidt in
Google Scholar
PubMed
Search for other papers by Sten Velschow in
Google Scholar
PubMed
Department of Pediatrics, Copenhagen University Hospital - Herlev & Gentofte, Copenhagen, Denmark
Search for other papers by Jesper Johannesen in
Google Scholar
PubMed
Search for other papers by Linda Maria Hilsted in
Google Scholar
PubMed
Search for other papers by Malene Schrøder in
Google Scholar
PubMed
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Introduction In an everyday endocrine setting, the dynamic response of hormones is assessed for the diagnosis and evaluation of several conditions such as adrenal insufficiency ( 1 ), acromegaly ( 2 ), and growth hormone deficiency ( 3
Search for other papers by Xiaonan Guo in
Google Scholar
PubMed
Search for other papers by Wenjing Hu in
Google Scholar
PubMed
Search for other papers by Xiaorui Lyu in
Google Scholar
PubMed
Search for other papers by Hanyuan Xu in
Google Scholar
PubMed
Search for other papers by Huijuan Zhu in
Google Scholar
PubMed
Search for other papers by Hui Pan in
Google Scholar
PubMed
Search for other papers by Linjie Wang in
Google Scholar
PubMed
Search for other papers by Hongbo Yang in
Google Scholar
PubMed
Search for other papers by Fengying Gong in
Google Scholar
PubMed
with acromegaly from four electronic databases showed that arginine and proline were the most altered pathways ( 48 ). Therefore, we assumed that the abnormal GH levels might be associated with arginine metabolism, thus arginine metabolism was well